Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer’s disease

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor linking environmental signals to immune regulation and neurodegeneration. While AHR agonists exert protective effects in Alzheimer’s disease (AD) models, their relevance in humans remains unclear. We investigated AHR agonistic activity in serum and cerebrospinal fluid (CSF) across AT1-defined AD subtypes and its association with amyloid beta (Aβ) metabolism. We measured AHR agonistic activity using a luciferase reporter assay in serum and cerebrospinal fluid (CSF) from 138 individuals (113 non-demented, 25 demented) classified by CSF Aβ1-42, Aβ1-42/Aβ1-40 ratio and pTau181 into four AT1 groups: A + T1 + (AD), A + T1- (isolated decrease of Aβ1-42/Aβ1-40 or Aβ1-42), A-T1 + (isolated tau pathology/PASSED), and A-T1- (biomarker-negative controls). Serum AHR agonistic activity was significantly reduced in biomarker-positive individuals compared to controls (Δ z-score = 2.25, 95% CI [1.33, 3.17], p < 0.001), with the most pronounced reductions observed in two distinct phenotypes: non-demented A-T1 + individuals (z-score = -2.33, 95% CI [-3.26, -1.40]) and A + T1 + patients with preserved CSF Aβ1-42 despite pathological Aβ1-42/Aβ1-40 ratios (p = 0.006 compared to A + T1 + with pathological Aβ1-42). Serum AHR activity correlated negatively with CSF Aβ1-40 (ρ = -0.31, p < 0.001) and Aβ1-42 (ρ = -0.20, p = 0.021) across all participants. The relationship between pTau181 and serum AHR activity showed significant effect modification by amyloidopathy (A) (interaction p < 0.0001): negative in A- individuals (β = -0.54, p < 0.0001) but positive at high pTau181 levels in A + cases (β = 0.12, p = 0.025). CSF AHR activity showed no significant differences between AT1 groups. Peripheral AHR agonistic activity is reduced in early and atypical AD phenotypes and correlates with amyloid peptides Aβ1-42 and Aβ1-40 in CSF. The amyloid status-dependent reversal of pTau181-AHR associations suggests distinct regulatory mechanisms across AT1 groups.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2026-02-06
DOI
https://doi.org/10.1186/s13195-026-01978-w
Primary Topic
Toxic Organic Pollutants Impact
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer’s disease

Veit Rothhammer, Juan Manuel Maler, Stefan Mestermann, Laura Rudtke et al.
Alzheimer s Research & Therapy
Toxic Organic Pollutants Impact
article

Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer’s disease

Veit Rothhammer, Juan Manuel Maler, Stefan Mestermann, Laura Rudtke, Leander Ammon, Piotr Lewczuk, Johannes Kornhuber, Timo Jan Oberstein, Thanos Tsaktanis
article en

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor linking environmental signals to immune regulation and neurodegeneration. While AHR agonists exert protective effects in Alzheimer’s disease (AD) models, their relevance in humans remains unclear. We investigated AHR agonistic activity in serum and cerebrospinal fluid (CSF) across AT1-defined AD subtypes and its association with amyloid beta (Aβ) metabolism. We measured AHR agonistic activity using a luciferase reporter assay in serum and cerebrospinal fluid (CSF) from 138 individuals (113 non-demented, 25 demented) classified by CSF Aβ1-42, Aβ1-42/Aβ1-40 ratio and pTau181 into four AT1 groups: A + T1 + (AD), A + T1- (isolated decrease of Aβ1-42/Aβ1-40 or Aβ1-42), A-T1 + (isolated tau pathology/PASSED), and A-T1- (biomarker-negative controls). Serum AHR agonistic activity was significantly reduced in biomarker-positive individuals compared to controls (Δ z-score = 2.25, 95% CI [1.33, 3.17], p < 0.001), with the most pronounced reductions observed in two distinct phenotypes: non-demented A-T1 + individuals (z-score = -2.33, 95% CI [-3.26, -1.40]) and A + T1 + patients with preserved CSF Aβ1-42 despite pathological Aβ1-42/Aβ1-40 ratios (p = 0.006 compared to A + T1 + with pathological Aβ1-42). Serum AHR activity correlated negatively with CSF Aβ1-40 (ρ = -0.31, p < 0.001) and Aβ1-42 (ρ = -0.20, p = 0.021) across all participants. The relationship between pTau181 and serum AHR activity showed significant effect modification by amyloidopathy (A) (interaction p < 0.0001): negative in A- individuals (β = -0.54, p < 0.0001) but positive at high pTau181 levels in A + cases (β = 0.12, p = 0.025). CSF AHR activity showed no significant differences between AT1 groups. Peripheral AHR agonistic activity is reduced in early and atypical AD phenotypes and correlates with amyloid peptides Aβ1-42 and Aβ1-40 in CSF. The amyloid status-dependent reversal of pTau181-AHR associations suggests distinct regulatory mechanisms across AT1 groups.

Alzheimer s Research & TherapyVol. 18(1)
Medical University of Białystok (PL), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universitätsklinikum Erlangen (DE), University Clinical Hospital In Bialystok (PL)
Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutsche Forschungsgemeinschaft
Openalex Percentile: Top 67%
Toxic Organic Pollutants Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.